NPI: 1275871907 · PORTSMOUTH, OH 45662 · Family Medicine Physician · NPI assigned 01/31/2013
Authorized official WHITLATCH, KRISTIE controls 18+ related entities in our dataset. Read more
| Authorized Official | WHITLATCH, KRISTIE (CEO/PRESIDENT) |
| NPI Enumeration Date | 01/31/2013 |
Other providers sharing the same authorized official: WHITLATCH, KRISTIE
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 17,602 | $622K |
| 2019 | 17,051 | $513K |
| 2020 | 11,166 | $360K |
| 2021 | 14,894 | $466K |
| 2022 | 19,159 | $453K |
| 2023 | 17,934 | $401K |
| 2024 | 15,738 | $432K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 32,879 | 30,877 | $1.45M |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 43,593 | 40,994 | $1.25M |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 7,349 | 6,950 | $273K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 15,023 | 13,750 | $102K |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1,163 | 1,034 | $66K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 1,006 | 935 | $53K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 996 | 915 | $29K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 2,507 | 2,279 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 7,343 | 6,704 | $10K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 148 | 143 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 270 | 262 | $2K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 215 | 199 | $1K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 34 | 29 | $1K |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 20 | 12 | $751.33 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 175 | 157 | $699.19 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 61 | 58 | $323.52 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 94 | 91 | $305.42 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 373 | 332 | $235.95 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 13 | 12 | $40.00 |
| 36415 | Collection of venous blood by venipuncture | 12 | 12 | $29.69 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 224 | 217 | $27.13 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 46 | 39 | $11.35 |